300039 Shanghai Kaibao Pharmaceutical
- 5.36
- -0.08-1.47%
Shanghai Kaibao Pharmaceutical News
Shanghai Kaibao Pharmaceutical (300039.SZ) won the Second Prize of National Science and Technology Progress Award.
On June 24, 2024, the National Science and Technology Achievement Conference of 2023 was held in Beijing, where Shanghai Kaibao Pharmaceutical Co. Ltd., of which Director Mu Jingwei participated, was awarded the second prize of the National Science and Technology Progress Award for "Integrated Innovation and Support System Creation and Application of Traditional Chinese Medicine Quality Detection Technology".
Shanghai Kaibao Pharmaceuticals (300039.SZ) plans to distribute 1 yuan per 10 shares, with ex-right and ex-dividend on June 19.
Shanghai Kaibao Pharmaceutical (300039.SZ) announced that it plans to distribute cash dividends of RMB 1.00 per 10 shares to all shareholders for the 2023 annual equity. The ex-dividend date is June 19, 2024.
Shanghai Kaibao Pharmaceutical (300039.SZ): Not currently involved in using AI for product development.
Shanghai Kaibao (300039.SZ) stated on the investor interaction platform on June 12 that the company is a comprehensive pharmaceutical enterprise mainly engaged in the research and development, production, and sales of modern traditional Chinese medicine, and is currently not involved in using AI for product development.
Shanghai Kaibao Pharmaceutical's Tareqing series products include Tareqing Injection and Tareqing Capsules.
Shanghai Kaibao (300039.SZ) stated on the investor interaction platform on June 12 that the Tantetiqing series products include Tantetiqing injection and Tantetiqing capsules. Tantetiqing injection, the main product, mainly has the effects of clearing heat, detoxifying, and resolving phlegm. It is mainly used for the treatment of bacterial or viral induced acute and chronic bronchitis, pneumonia, and upper respiratory tract infection diseases. Tantetiqing injection is included in the prevention and control of "avian influenza", "H1N1 influenza", "H7N9 influenza", "hand-foot-mouth disease", "dengue fever", "Ebola", "Middle East respiratory syndrome", "COVID-19" by the National Health Commission and Traditional Chinese Medicine.
Shanghai Kaibao (300039.SZ): The new land is currently being used for modern Chinese medicine intelligent manufacturing industrialization projects
Gelonghui May 11 丨 Shanghai Kaibao (300039.SZ) held a performance briefing on May 10, 2024, to discuss “Is buying land for synthetic organisms?” The company replied that the new land is currently being used for modern traditional Chinese medicine intelligent manufacturing industrialization projects, and future additions will be promptly disclosed.
Shanghai Kaibao (300039.SZ): Products under development are useful for synthetic biology technology
Gelonghui May 11 丨 Shanghai Kaibao (300039.SZ) held a performance briefing on May 10, 2024 to discuss “Your company has a biomedical concept, does it have synthetic biomedical products? Or are synthetic bio-health products being developed?” The company replied that the products it is developing are useful for synthetic biology technology.
Shanghai Kaibao (300039.SZ): The Youxinding Project has entered phase III clinical research
Gelonghui May 11 丨 Shanghai Kaibao (300039.SZ) held a performance briefing on May 10, 2024 to discuss “How is Youxinding progressing?” The company replied that according to the information publicly released by the Drug Evaluation Center of the State Drug Administration, the project has entered phase III clinical research.
Express News | Shanghai Kaibao: Plans to invest in the construction of a modern Chinese medicine intelligent manufacturing industrialization project
Shanghai Kaibao (300039.SZ) has been re-certified as a high-tech enterprise
Gelonghui, February 26 | Shanghai Kaibao (300039.SZ) announced that the company successfully passed the high-tech enterprise re-certification and recently received the “High-tech Enterprise Certificate” jointly issued by the Shanghai Municipal Science and Technology Commission, the Shanghai Municipal Finance Bureau, and the Shanghai Taxation Bureau of the State Administration of Taxation. The certificate number is GR202331001517. The certificate number is GR202331001517. The certificate is issued on November 15, 2023 and is valid for three years.
Shanghai Kaibao (300039.SZ): Net profit is expected to increase 45%-85% year-on-year in 2023
On January 30, Ge Longhui | Shanghai Kaibao (300039.SZ) announced that net profit for 2023 is estimated to be 276.6665 million yuan to 35,29883 million yuan, an increase of 45%-85% over the same period last year, after deducting non-net profit of 254.08083 million yuan to 314.423 million yuan, an increase of 41% to 77% over the same period last year. The impact of the company's non-recurring profit and loss on net profit in 2023 is estimated to be around RMB 330.00 million, and the amount of impact of non-recurring profit and loss on net profit in the previous year was RMB 13.211 million.
Shanghai Kaibao (300039.SZ): 93 drugs included in the national medical insurance catalogue
Shanghai Kaibao (300039.SZ) announced that the company and its wholly-owned subsidiary Shanghai Kaibao Xinyi (Xinxiang) Pharmaceutical Co., Ltd...
Traditional Chinese medicine and anti-influenza concept stocks rallied, Jinling Pharmaceutical rose and stopped
Gelonghui, December 13 | Jinling Pharmaceutical rose and stopped in a straight line, with Shanghai Kaibao, Wohua Pharmaceutical, Zuoli Pharmaceutical, Yisheng Pharmaceutical, and Longshen Rongfa following suit.
Shanghai Kaibao (300039.SZ): “Traditional Chinese Medicine Internal Medicine Clinical Diagnosis and Treatment Guidelines - Mycoplasma Pneumonia” issued by the Chinese Society of Traditional Chinese Medicine. Phlegm fever-clearing injections are listed as
On December 7, Gelonghui, Shanghai Kaibao (300039.SZ) stated on the investor interactive platform that the phlegm fever-clearing series products include: phlegm fever-clearing injections, phlegm fever-clearing capsules, and phlegm fever-clearing oral solutions under development. The main effects of phlegm clearing injections are to clear heat, detoxify, and relieve phlegm. They are mainly used for the treatment of acute and chronic bronchitis, pneumonia, and upper respiratory tract infections caused by bacteria or viruses. Phlegm fever-clearing injections for prevention and control of “human avian influenza,” “influenza A (H1N1),” “influenza A (H7N9),” “hand, foot and mouth disease,” “dengue fever,” “Ebola,” “Middle East respiratory syndrome,” and “COVID-19.”
Shanghai Kaibao (300039.SZ): The leading product, phlegm fever-clearing injection, is an exclusive patented product and is a Class II new Chinese medicine in the country
Gelonghui November 21丨Shanghai Kaibao (300039.SZ) said on the investor interactive platform that the company's leading product, Phlegm Heqing Injection, is an exclusively patented product and is a Class II new Chinese medicine in the country. In the prevention and control of “human avian influenza,” “influenza A (H1N1),” “influenza A (H1N1),” “influenza A (H7N9),” “hand, foot and mouth disease,” “dengue fever,” “Ebola,” and “Middle East respiratory syndrome,” etc., it was classified by the National Health and Health Commission and the Administration of Traditional Chinese Medicine as a clinical guideline or treatment plan drug. In 2006, it was classified by the National Development and Reform Commission as a “reserve drug for proprietary Chinese medicine for influenza prevention”, and became a national strategic reserve drug
Shanghai Yizhong (688091.SH), the main shareholder of Shanghai Kaibao (), did not reduce its holdings at the end of the holdings reduction period
According to the Zhitong Finance App, Shanghai Yizhong (688091.SH) announced that Shanghai Kaibao Pharmaceutical Co., Ltd. (“Shanghai Kaibao”), which holds more than 5% of the company's shares, has not reduced its holdings in the company, and the current holdings reduction period has expired.
[Instant Analysis of BT Financial Report] Shanghai Kaibao 2023 Third Quarter Report: Both Operating Revenue and Net Profit Increased, and R&D Investment Increased
Announcement time of this financial report: 2023-10-17 19:41:35 Shanghai Kaibao Pharmaceutical Co., Ltd. (stock code: 300039) is a comprehensive pharmaceutical enterprise focusing on R&D, production and sales of modern traditional Chinese medicines. The company has an independent and complete raw material procurement, R&D, production and sales system, and has multiple subsidiaries in different fields, covering product lines in respiratory, cardiovascular, and digestive fields. The company is committed to promoting the development of the traditional Chinese medicine health industry, cooperating with well-known universities and research institutes, and continuously promoting technology research and development and innovation. At the same time, the company focuses on marketing and sales
Shanghai Kaibao (300039.SZ): Net profit of 608.36,800 yuan in the third quarter increased 69.77% year-on-year
Glonghui, October 17: Shanghai Kaibao (300039.SZ) announced its report for the third quarter of 2023. Revenue for the reporting period was 308 million yuan, up 18.53% year on year; net profit attributable to shareholders of listed companies was 608.36,800 yuan, up 69.77% year on year; net profit attributable to shareholders of listed companies was 60.3021 million yuan after non-recurring profit and loss, up 75.27% year on year; basic earnings per share were 0.0582 yuan.
Shanghai Kaibao (300039.SZ): Two supervisors and executives voluntarily terminated the share reduction plan ahead of schedule and did not reduce holdings during the holdings reduction period
Shanghai Kaibao (300039.SZ) issued an announcement. The company recently received the appointment of the company's supervisor Liu Shaoyong and director respectively...
Shanghai Kaibao (300039.SZ): Liu Shaoyong and Ren Liwang terminated their holdings reduction plans ahead of schedule and did not reduce their holdings
GLONGHUI, October 16丨Shanghai Kaibao (300039.SZ) announced that the company recently received the “Notice Letter on Early Termination of the Shareholding Reduction Plan” issued by Mr. Liu Shaoyong and Mr. Ren Liwang respectively. According to their own financial arrangements, out of confidence in the company's continued development, the aforementioned shareholders voluntarily terminated this share reduction plan ahead of schedule after comprehensive considerations. From the date the plan was implemented to the date the announcement was disclosed, neither Mr. Liu Shaoyong nor Mr. Ren Liwang reduced their holdings of the company's shares.
Shanghai Kaibao (300039.SZ) issued an advance increase. Net profit for the first three quarters is expected to be 178 million yuan to 213.5 million yuan, an increase of 50%-80% over the previous year
Shanghai Kaibao (300039.SZ) released its performance forecast for the first three quarters of 2023. The company is expected to go public...
Analysis
Price Target
No Data
